Receive The Newest Study Notifications

DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 -- Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides1 (Clostridium) difficile infections...

Today, the overall results of six Phase 2 clinical trials of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) were published in the peer-reviewed journal Psychopharmacology. The paper is the most comprehensive analysis yet...

- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab...

I Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA). The clinical trial...

Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, the  Association...

  Phase I clinical trial to evaluate safety and tolerability of ATR-002 in healthy volunteers ATR-002 expected to show high resilience to viral resistance and prolonged treatment window Novel approach to treating influenza, one of the most prominent global health...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS, the...

-Company strengthens board of directors and scientific advisory board with appointments of Mike Raab and Benjamin Cravatt-- Tempest Therapeutics Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class immunomodulatory small...

FDA Lifts Clinical Hold on Second Cohort to Allow Dose Escalation Robust Preliminary Anatomical Response from First Cohort Leads Adverum to Begin Dosing Second Cohort at Lower Dose MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc....

 Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL.  Viracta researchers and study...

L3 Clinical Trials, the Clinical Research Organization (CRO) division of L3 Healthcare (L3), announces the company is now a certified designer of the Medrio EDC Software. L3 Clinical Trials provides comprehensive and specialized CRO services for start-up and mid-size...

NeuClone Pharmaceuticals Ltd. (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it will initiate the Phase I clinical trial of its Stelara® (ustekinumab) biosimilar in the second...

Recognizing the Support of the National Institutes of Health and the HIV Vaccine Trials Network in Advancing GeoVax’s HIV Vaccine Development Efforts GeoVax Labs, Inc. (OTCQB: GOVXD), a biotechnology company developing human vaccines, announced today its observance of...

Placebell technology designed to limit the negative impact of the placebo effect in clinical trials Tools4Patient, S.A., developer of tools to optimize and accelerate drug development programs, today announced it raised €4 million ($4.5 million) in an oversubscribed...

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the initiation of the Phase 2 portion of a global, open-label, randomized clinical trial studying the...

— Clinical Proof-of-Concept Data Expected in Fourth Quarter of 2019 — Dicerna Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the dosing of the first...

Tempest Therapeutics Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class immunomodulatory small molecules targeting diverse cancers, today announced that the first patient has been dosed with TPST-1120 in a Phase I/Ib trial to...

Approval allows Zai Lab to enroll patients in a global Phase 3 clinical trial in collaboration with Entasis Therapeutics More than 200,000 cases of A. baumannii infections in China annually - Approximately 60% are carbapenem-resistant - High mortality rate (30-60%)...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA). The clinical trial protocol...

National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) for the Treatment of Recurrent Malignant Gliomas Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary...